Pfizer will submit data to the FDA regarding the fourth Covid shot.

According to CEO Albert Bourla, Pfizer is submitting data to the Food and Drug Administration for a fourth dose of the Covid-19 vaccine.

“Obviously, Omicron’s environment is needed to boost the immune response,” he told CNBC in an interview on Friday.

Full coverage of the Covid-19 pandemic

The protection from the first two doses of the Pfizer-BioNTech vaccine was substantially weakened against the Omicron variant, but Booster Shot restored much of that protection.

But on Friday, Pfizer scientists saw protection from the first booster shot begin to decline against Omicron after three to four months, and a fourth dose may be needed, Bula said. Said there is.

“We will submit an important data package to the FDA regarding the need for a fourth dose,” he said, and said the FDA and the Centers for Disease Control and Prevention need to reach their own conclusions.

In other countries, including Chile, Israel and Sweden, a fourth vaccination has already been granted for certain vulnerable populations.

Pfizer spokesman Kit Longley told NBC News in another statement that the company would submit data to the FDA on its fourth shot when it was “ready.”

“These results are early and preliminary, with regulatory and health authorities to continue to collect and evaluate all available data and inform regulatory and health authorities of the Covid-19 vaccine strategy as the virus evolves. We will continue to have an open dialogue. “

Covid cases of Omicron fuel across the country have dropped significantly in recent weeks after reaching record highs in January.

download NBC News App For full coverage of the Covid-19 pandemic

Federal health officials say they continue to assess whether additional doses are needed, especially in the fall when Covid cases are expected to increase again. Vaccine makers, including Pfizer and Moderna, say they are ready to update this, falling to target circulating dominant variants.

Dr. Archana Chatterjee, Vaccine Specialist and Dean of Rosalind Franklin University’s Chicago Medical College, agrees that many health professionals will need additional doses in the future.

The CDC currently recommends boosters 5 months after receiving a second dose of Pfizer or Moderna vaccine, or 2 months after receiving a single dose of Johnson & Johnson vaccine.

Dr. Paul Offit, a vaccine expert at the Philadelphia Children’s Hospital, said it is not recommended for everyone if additional injections are needed.

People living in nursing homes, the elderly, people with immunodeficiency, and people at high risk may benefit from additional doses, he said.

Harvard epidemiologist Bill Hanage agrees that certain groups may require additional doses, and antibodies during the summer when the virus may continue to spread at low levels. He said the level could drop further.

However, young people at low risk of serious illness are unlikely to benefit from additional doses, he added.

Bula said on Friday that older people and those with underlying health are at greatest risk and are likely to require additional doses.

follow NBC Health on twitter & Facebook..

About the author


Leave a Comment